Cells from the spleens and thymuses of BALB/c mice whose Moloney sarcoma virus (MSV)induced, primary sarcomas have regressed 2-3 months earlier (''MSV regressors") or are in the process of regressing can, when adoptively transferred to syngeneic mice given MSV at the age of 20 days, prevent the natural regression of the MSV sarcomas in the recipient mice. The cells responsible for this tumor-enhancing effect express the Thy 1 marker. They are not demonstrable in the thymuses of normal untreated mice or in mice that have either been immunized against or are bearing methylcholanthrene-induced sarcomas. The tumor-enhancing cells are not destroyed after administration of 400 rads (1 rad = 1.00 X 10-2 i/kg) of whole body radiation. However, the effect of the irradiated cells is seen only in the presence of a nonirradiated T-cell population, represented in the thymuses of normal control mice, with which we postulate that they interact. 
The Moloney sarcoma virus (MSV) induces sarcomas in mice, which, depending on the age or strain of the mice and the virus dose, either grow progressively and kill the host or spontaneously regress (1) . Immune reactions to MSV-associated tumor antigens mediated by T, K, and NK cells (2) , as well as by humoral antibodies (3) , have been detected. T-cell-mediated immunity appears to play the major role in tumor regression.
Suppressor T cells demonstrable in vitro have been associated with progressive growth of MSV-induced sarcomas in mice receiving Freund's adjuvant (4) , and may regulate the host's immune response to such tumors. In this paper we show that T cells from the spleens and thymuses of mice with growing MSV sarcomas and from mice whose sarcomas have regressed can prevent the normal regression of MSV-induced tumors.
These cells are antigen specific and they are relatively radioresistant. They probably are suppressor activator cells (5) which interact with radiosensitive suppressor acceptor T cells. Relatively radioresistant suppressor cells, capable of enhancing tumor growth in the presence of radiosensitive host T cells, are also demonstrated in mice immune to a methylcholanthreneinduced sarcoma, which does not express any murine leukemia virus (MuLV) antigens. This suggests that the principal findings obtained with MSV-induced sarcomas have relevance to many different tumor systems.
MATERIALS AND METHODS
Mice. BALB/c mice were bred by brother/sister mating in our laboratory and' were regularly checked for their ability to accept intrastrain skin grafts. Approximately 20-day-old mice were used for experiments with MSV-induced sarcomas (except in one experiment in which we used 40-day-old mice). Fortyday-old mice were used for all experiments with other tumors. The mice were sex matched within each experiment (females were used primarily). Mice were randomized into various experimental and control groups and were individually ear tagged.
MSV-Induced Sarcomas. MSV, lot B146 (4/78), was obtained from J. Gruber (National Institutes of Health). Mice were inoculated intramuscularly into each thigh with 0.1 ml/site of a 1:7 diluted virus preparation, which provided two "tumor sites" per mouse. Each site was scored independently for the development of tumor. With the MSV dose given, tumors were generally observed at the site of virus inoculation within 6-8 days and at virtually 100% of the sites. These tumors regressed in approximately 95% of the 20-day-old mice within a 2-to 3-week period and in about 98% of the 40-day-old mice within 2 weeks.
Methylcholanthrene-Induced Tumors. A total of six transplantable BALB/c tumors induced by 3-methylcholanthrene were used: MCA-1315, -1321, -1425, -1440, -1460, and -1563. The first five of these are fibrosarcomas, while MCA-1563 is a methylcholanthrene-induced carcinoma of the bladder. MCA-1325, -1321, and -1425 express MuLV antigen gp7O at the cell surface (6) Table 4 .
Adoptively transferred (nonirradiated) MSV regressor thymocytes prevented the regression of primary MSV-induced sarcomas, as in our previous experiments (compare group C in Table 4 with group E in Table 1 ). Sublethal irradiation (400 rads) of the MSV regressors abolished the tumor-enhancing ability of their thymocytes when tested in sublethally irradiated recipients. However, significant tumor enhancement was observed if the irradiated recipients also received normal nonir- (Table 4 ). 001 * Thymus cells were derived from 60-day-old mice, some of which 10 days previously had received 5 X 106 irradiated (15,000 rads) cells from MCA-1460 subcutaneously on both sides of the back ("1460-immune" mice) and some of which were agematched normal, untreated BALB/c mice; the immune mice received 400 rads whole body irradiation the day before they were killed and thymus cell suspensions prepared. 2 x 107 thymus cells per mouse were given subcutaneously (107 cells of each type in group D) as a mixture with the tumor cells. t Mice were preimmunized with irradiated (15,000 rads) MCA-1460 cells, received 400 rads whole body irradiation 9 days later, and were inoculated subcutaneously on both sides of the back with 104 MCA-1460 cells the following day. Each mouse was scored for the presence of tumor, each side (tumor "site") being recorded separately. Data presented from one experiment with five age-matched BALB/c males per group. Nineteen days after inoculation. A site was scored as positive if it had a tumor of at least 3 mm mean diameter. § The statistical significance of differences between groups in mean tumor diameters was determined by Student's t tests; significance in frequencies of tumor takes was determined from Fischer exact tests.
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5298 Immunology: Hellstrom et al. DISCUSSION As an approach to investigating the role of suppressor T cells in tumor immunity, we have studied the effect of adoptively transferred syngeneic lymphoid cells on the growth of primary MSV-induced sarcomas in BALB/c mice and, in one experiment, on the growth of a transplantable, methylcholanthrene-induced and MuLV antigen-negative BALB/c sarcoma (MCA-1460).
Spleen and thymus cells from mice in which primary MSV-induced sarcomas had regressed 2-3 months previously inhibited the expected regression of primary MSV sarcomas when given at the same time as MSV or 6 days later. Lymph node cells, on the other hand, were much less effective. Thymus cells from mice whose MSV tumors were in the process of regressing also inhibited regression of the primary sarcomas, and thymus cells from mice with growing sarcomas were effective, although to a lesser extent. The effect was most pronounced when the regressor cells were given on the same day as the MSV. The responsible cells were T cells because treatment with anti-Thy 1 serum and complement abolished their ability to prevent tumor regression. Preliminary data (unpublished) suggest that they are sensitive to treatment with an anti-Lyt 1 serum (in the presence of complement), but less so to treatment with anti-Lyt 2 serum. Thymus cells from normal syngeneic mice of various ages have not been found to affect tumor regression, nor have thymus cells from mice immunized to, or bearing a variety of, methylcholanthrene-induced tumors.
We then tested the radiosensitivity of the tumor-enhancing effect of thymocytes from MSV regressors. This was done in view of the evidence that suppressor T cell-mediated phenomena are commonly radiosensitive (7, 9) . It became clear that the ability of adoptively transferred MSV regressor thymocytes to interfere with the regression of primary MSV sarcomas in unirradiated recipients is relatively radioresistant, but only as long as a radiosensitive cell population in the recipient remains in the system. Thymus cells from young, untreated syngeneic mice were found to provide such a cell population, pointing very strongly toward a requirement for T cells.
Finally, we studied whether relatively radioresistant cells with the ability to enhance tumor growth in the presence of radiosensitive, nonimmune T cells were present also in mice that had been immunized to a tumor not expressing MuLV antigens. This was done by working with a transplantable BALB/c sarcoma, MCA-1460. Findings were obtained that were similar to those made with MSV sarcomas.
On the basis of the present as well as previous observations, we make the following tentative conclusions about suppressor cells in tumor immunity. Sera from mice with growing tumors, including MSV sarcomas, can inhibit ("block") cell-mediated cytotoxicity to the respective tumors in vitro (10) , and T cells from tumor-bearing mice can produce specific blocking factors in vitro (11) . The specific blocking factors include tumor antigen, antigen-antibody complexes, and, most likely, a T cellderived immunosuppressive molecule (10) . There is evidence that tumor antigens and antigen-antibody complexes can enhance tumor growth in VIVO by activating a population of suppressor T cells (8, 9, 12, 13) . Thus, one can postulate that antigen released from tumor cells induces, by acting alone or as a complex with antibody, the formation of suppressor cells which, by preventing the establishment of effective tumor immunity, will enhance tumor growth (8) . A radiosensitive T-cell population plays a role in this tumor enhancement (8, 9) . As shown by the present findings, an early event during tumor development is the emergence of a relatively radioresistant population of suppressor T cells, which is present also in mice that are immune and tumor free. These cells prevent the development of effective antitumor immunity by interacting with a population of radiosensitive T cells, which are present also in the thymus of untreated mice and may be similar to the radiosensitive suppressor cells previously identified (8, 9) . The former, immune cells are probably suppressor activator cells, and the latter ones are probably suppressor acceptor cells that are needed for generating suppressor effector cells (5) . To the extent studied, the activator T cells are antigen specific. We postulate that the suppressor mechanism implicated is at least partially responsible for the fact that, after initial regression, MSV-induced sarcomas recur relatively frequently (1) and that even the most immunogenic tumors induce a host response that is easily overcome if a large tumor cell challenge is given.
Finally, we would like to introduce an alternative interpretation of our findings, which has been suggested by R. T. Prehn (personal communication) and which is based on the concept of immunostimulation of tumor growth (14) . As suggested by Prehn, our data might be explained by postulating that normal radiosensitive thymus cells, in the presence of a radioresistant immune population, are stimulatory to tumor cells whereas the radioresistant immune cells, themselves, are not.
We have become aware that findings that are rather similar to those described here have been recently made in a tumor allograft system (15 
